Showing 4031-4040 of 5957 results for "".
- In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streakshttps://modernod.com/news/in-japanese-study-vabysmo-achieves-primary-endpoint-in-phase-3-study-for-angioid-streaks/2482231/Japan-based Chugai Pharmaceutical announced that the Japanese phase 3 study (NIHONBASHI study), evaluating Roche and Genentech's Vabysmo (faricimab) for angioid streaks associated with neovascularization, met its primary endpoint, demonstrating statistically signific
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- ViGeneron Announces First Patient Dosed in Phase 1b Trial of VG901 for the Intravitreal Treatment of RPhttps://modernod.com/news/vigeneron-announces-first-patient-dosed-in-phase-1b-trial-of-vg901-for-the-intravitreal-treatment-of-rp/2482224/ViGeneron announced that the first patient has been dosed in its phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage it
- Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the Worldhttps://modernod.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/Orbis has announced a new partnership with Heidelberg Engineering, which will fund teaching opportunities and research focused on training eye care professionals around the world via Cybersight—Orbis’s award-winning telemedicine and e-learning platform. It will als
- Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plughttps://modernod.com/news/orasis-introduces-soft-plug-extended-duration-180-t-tapered-plug/2482222/Oasis Medical has launched the SOFT PLUG Extended Duration 180-T Tapered Plug. SOFT PLUG Extended Duration 180-T Tapered Plugs are designed with a .25mm tapered end for ease of insertion into the punctal opening, according to Oasis. The plug then gradu
- FDA Approves Ocugen's IND Amendment to Initiate Phase 3 Trial for RP Gene Therapyhttps://modernod.com/news/fda-approves-ocugens-ind-amendment-to-initiate-phase-3-trial-for-rp-gene-therapy/2482220/Ocugen announced that the FDA has cleared the company’s investigational new drug (IND) amendment to initiate a phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “The initiation of the OCU400 phase
- TheiaNova Selected as Finalist at Eyecelerator for Keratoconus Therapy; Launches Capital Raise for Clinical Trialshttps://modernod.com/news/theianova-selected-as-finalist-at-eyecelerator-for-keratoconus-therapy-launches-capital-raise-for-clinical-trials/2482215/New Zealand-based TheiaNova has delivered the company’s pitch as a finalist in the renowned Eyecelerator event in Boston. At the Eyecelerator event, where TheiaNova participated as a finalist, CEO Carissa Fonseca announced the company’s efforts to raise $10 million 
- RxSight Launches LAL+ and Features Multiple Doctor Presentations at ASCRShttps://modernod.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small cont
- Eversight Center Awards 2024 Eye & Vision Research Grantshttps://modernod.com/news/eversight-center-awards-2024-eye-vision-research-grants/2482211/The Eversight Center for Vision and Eye Banking Research in Cleveland, Ohio, recently announced it has awarded four grants to investigators at Tufts University in Boston, Massachusetts; Wayne State University in Detroit, Michigan; and University of Michigan in Ann Arbor, Michigan, to advance prom
- Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-dutch-ophthalmic-research-center/2482210/Carl Zeiss Meditec announced it has secured all required regulatory approvals and completed the acquisition of Dutch Ophthalmic Research Center (DORC). IN December, Zeiss announced its plans to acquire from the investment firm Eurazeo SE (Paris, France) for about €985 million ($1.0